Identification and Characterization of a Non-Interferon Antileishmanial Macrophage Activating Factor (Antileishmanial MAF)

  • Anthony Van Niel
  • Susan E. Zacks
  • John R. David
  • Heinz G. Remold
  • Weishui Y. Weiser
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 239)


Macrophages, the final effector cells in many cellular immune responses are capable of destroying a variety of intracellular pathogens such as viruses, fungi, chlamydia, rickettsiae and leishmania (1,2) as well as neoplastic cells (3). However, the biochemical identity of macrophage activating factor (MAF), and therefore the elucidation of its mechanism of action on macrophages have remained ill-defined. In part, this has been due to the limited amounts of MAF produced under conventional conditions, amounts insufficient to achieve a full biochemical purification of this factor. In addition, conventional culture supernatants of activated T cells normally contain a heterogeneous mixture of lymphokines, such as interferon-gamma (IFN-gamma), granulocyte macrophage colony stimulating factor (GM-CSF) and macrophage migration inhibitory factor (MIF) that can all affect the functions of macrophages. Although both human and murine interferon-gamma have been attributed to be the lymphokines to activate macrophages for enhanced oxidative and antimicrobial activity (4–7), numerous reports also demonstrated the existence of non-IFN-gamma MAFs (8–12).


Migration Inhibitory Factor Granulocyte Macrophage Colony Stimulate Factor Macrophage Migration Inhibitory Factor Antileishmanial Activity Intracellular Killing 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Nacy, C.A., C.N. Oster, S.L. James, and M.S. Meltzer. 1984. Activation of macrophages to kill Rickettsiae and Leishmania: Dissociation of intracellular microbicidal activities and extracellular destruction of neoplastic and helminth targets. Contemporary Topics in Immunobiology. 13: 146.Google Scholar
  2. 2.
    Murray, H.W. 1984. Macrophage activation: Enhanced oxidative and antiprotozoal activity. Contemporary Topics in Immunobiology 13: 97.PubMedGoogle Scholar
  3. 3.
    Adams, D.O., and T.A. Hamilton. 1984. The cell biology of macrophage activation. Ann. Rev. Immunol. 2: 283.CrossRefGoogle Scholar
  4. 4.
    Murray, H.W., and D.M. Cartelli. 1983. Killing of intracellular Leishmania donovani by human mononuclear phagocytes. Evidence for oxygen-dependent and -independent leishmanicidal activity. J. Clin. Invest. 72: 32.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Nathan, C.F., H.W. Murray, M.E. Wiebe, and B.Y. Rubin. 1983. Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med. 158: 670.PubMedCrossRefGoogle Scholar
  6. 6.
    Murray, H.W., G.L. Spitalny, and C.F. Nathan. 1985. Activation of mouse peritoneal macrophages in vitro and in vivo by IFN-gamma. J. Immunol. 134: 1619.PubMedGoogle Scholar
  7. 7.
    Rothermel, C.D., B.Y. Rubin, E.A. Jaffe, and H.W. Murray. 1986. Oxygen-independent inhibition of intracellualr Chlamydia psittaci growth by human monocytes and interferon-gamma-activated macrophages. J. Immunol. 137: 689.PubMedGoogle Scholar
  8. 8.
    Gately, C.L., S.M. Wahl, and J.J. Oppenheim. 1983. Characterization of hydrogen peroxide-potentiating factor, a lymphokine that increases the capacity of human monocyte and monocyte-like cell lines to produce hydrogen peroxide. J. Immunol. 131: 2853.PubMedGoogle Scholar
  9. 9.
    Buchmuller, Y., W.Y. Weiser, and H. Remold. 1985. Partial purication and characterization of a human lymphokine which induces antileishmanial activity in mouse macrophages. Cell. Immunol. 90: 242.PubMedCrossRefGoogle Scholar
  10. 10.
    Lee, J.C., L. Rebar, P. Young, F.W. Ruscetti, N. Hanna, and G. Poste. 1986. Identification and characterization of a human T-cell line-derived lymphokine with MAF-like activity distinct from interferon-gamma. J. Immunol. 136: 1322.PubMedGoogle Scholar
  11. 11.
    Hoover, D.L., D.S. Finbloom, R.M. Crawford, C.S. Nacy, M. Gilgreath, and M.S. Meltzer. 1986. A lymphokine distinct from interferon-gamma that activates human monocytes to kill Leishmania donovani in vitro. J. Immunol. 136: 1329.PubMedGoogle Scholar
  12. 12.
    Grabstein, K.H., D.L. Urdal, R.J. Tushiuski, D.Y. Mochizuki, V.L. Price, M.A. Cantrell, S. Gillis and P. Conlon. 1986. Induction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factor. Science 232: 506.PubMedCrossRefGoogle Scholar
  13. 13.
    Weiser, W.Y., H.G. Remold, and J.R. David. 1985. Generation of human hybridomas producing migration inhibitory factor (MIF) and of murine hybridomas secreting monoclonal antibodies to human MIF. Cell. Immunol. 90: 167.PubMedCrossRefGoogle Scholar
  14. 14.
    Weiser, W.Y., H.G. Remold, L.H. Block, and J.R. David. 1984. Dissociation of human interferon-gamma like activity from migration inhibitory factor. Cell. Immunol. 88: 109.PubMedCrossRefGoogle Scholar
  15. 15.
    Wong, G.G., J.S. Witek, PA. Temple, K.M. Wilkens, A.C. Leary, D.P. Luxenberg, S.S. Jones, E.L. Brown, R.M. Kay, E.C. Orr, C. Shoemaker, D.W. Golde, R.J. Kaufman, R.M. Hewick, E. Wang, and S.C. Clark. 1985. Human GM-CSF: Molecular cloning of the complementary DNA and purification of the natural and recombinant proteins. Science 228: 810.PubMedCrossRefGoogle Scholar
  16. 16.
    Koren, H.S., and R.B. Herberman. 1985. The current status of human monocyte mediated cytotoxicity against tumor cells. J. Leukocyte Biol. 38: 441.PubMedGoogle Scholar
  17. 17.
    Burgess, A.W., and D. Metcalf. 1980. The nature and action of granulocyte-macrophage colony stimulation factor. Blood 56: 947.PubMedGoogle Scholar
  18. 18.
    Casson, J.C., R.H. Weisbart, S.E. Kaufman, S.C. Clark, and R.M. Hewick. 1984. Purified human granulocyte-macrophage colony-stimulating factor: Direct action on neutrophils. Science 226: 1339.CrossRefGoogle Scholar
  19. 19.
    Silberstein, D.S., W.F. Owen, J.C. Gasson, J.F. Dipersio, D.W. Gold, J.C. Bina, R. Soberman, K.F. Austen, and J.R. David. 1986. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J. Immunol. 137: 3290.PubMedGoogle Scholar
  20. 20.
    Handman, E., and A.W. Burgess. 1979. Stimulation by granulocyte-macrophage colony-stimulating factor of Leishmania tropica killing by macrophages. J. Immunol. 122: 1134.PubMedGoogle Scholar
  21. 21.
    Ralph, P., C.A. Nacy, M.S. Meltzer, N. Williams, I. Nakoinz, and E.J. Leonard. 1983. Colony-stimulating factors and regulation of macrophage tumoricidal and microhicidal activities. Cell. Immunol. 76: 10.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1988

Authors and Affiliations

  • Anthony Van Niel
    • 1
  • Susan E. Zacks
    • 1
  • John R. David
    • 1
  • Heinz G. Remold
    • 1
  • Weishui Y. Weiser
    • 1
  1. 1.Department of Medicine, Harvard Medical School and Department of Rheumatology and ImmunologyBrigham and Women’s HospitalBostonUSA

Personalised recommendations